Low-molecular-weight Fucoidan (LMF) (also known as Oligo-Fucoidan and LMW Fucoidan) has been found to attenuate the adverse effects of gemcitabine and cisplatin and to inhibit cancer cachexia-related muscle atrophy during chemotherapy43, which induces NF-κB, myostatin and activin A expression. Here, MSTN is linked to cancer.